Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Refractory/Relapsed Diffuse Large B-cell Lymphoma Patients with Failure of CAR-T Therapy
In the challenging field of hematology, the search for effective treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) after CAR-T therapy failure is crucial. Professor Professor Haiwen Huang from The First Affiliated Hospital of Soochow University leads an innovative study exploring allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a promising alternative. This collaborative research not only offers new hope for R/R DLBCL patients but also showcases the pioneering spirit driving advancements in oncology. By providing valuable insights into allo-HSCT's potential, Professor Huang and his team contribute significantly to the evolving landscape of cancer treatment, highlighting the importance of innovation and teamwork in improving patient care.